|
|
Volumn 92, Issue 11, 2000, Pages 866-868
|
|
Plasminogen activator proteins tested as prognostic markers.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
CMF REGIMEN;
CYCLOPHOSPHAMIDE;
FLUOROURACIL;
METHOTREXATE;
PLASMINOGEN ACTIVATOR;
PLASMINOGEN ACTIVATOR INHIBITOR 1;
SERINE PROTEINASE INHIBITOR;
TUMOR MARKER;
UROKINASE;
ADJUVANT CHEMOTHERAPY;
ARTICLE;
BREAST TUMOR;
DISEASE FREE SURVIVAL;
ENZYME LINKED IMMUNOSORBENT ASSAY;
FEMALE;
GERMANY;
HUMAN;
METABOLISM;
MORTALITY;
MULTICENTER STUDY;
PATHOLOGY;
PREDICTION AND FORECASTING;
PROGNOSIS;
PROSPECTIVE STUDY;
RISK;
TIME;
TREATMENT OUTCOME;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
BREAST NEOPLASMS;
CHEMOTHERAPY, ADJUVANT;
CYCLOPHOSPHAMIDE;
DISEASE-FREE SURVIVAL;
ENZYME-LINKED IMMUNOSORBENT ASSAY;
FEMALE;
FLUOROURACIL;
GERMANY;
HUMANS;
METHOTREXATE;
MULTICENTER STUDIES;
ODDS RATIO;
PLASMINOGEN ACTIVATOR INHIBITOR 1;
PLASMINOGEN ACTIVATORS;
PREDICTIVE VALUE OF TESTS;
PROGNOSIS;
PROSPECTIVE STUDIES;
SERINE PROTEINASE INHIBITORS;
TIME FACTORS;
TREATMENT OUTCOME;
TUMOR MARKERS, BIOLOGICAL;
URINARY PLASMINOGEN ACTIVATOR;
MLCS;
MLOWN;
|
|
EID: 0034616573
PISSN: 00278874
EISSN: None
Source Type: Journal
DOI: 10.1093/jnci/92.11.866 Document Type: Article |
|
Times cited : (3)
|
|
References (0)
|
